**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****Inventors:** Hans-Ulrich DEMUTH et al.**Serial No.:** 10/727,209**Attorney Docket No.:** PBD-00016-C2
Formerly 20784/3-CON-2**Filed:** December 02, 2003**Art Group:** 1651**Examiner:** Not Yet Assigned**Title:** NOVEL EFFECTORS OF
DIPEPTIDASE IV

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

OSI Pharmaceuticals, Inc.

By Shu M. Lee
Shu M. LeeDate 09 Aug 2005

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450


**REVOCATION AND NEW POWER OF ATTORNEY
AND CHANGE OF CORRESPONDENCE ADDRESS**

Prosidion Limited is the assignee of 100% interest, as evidenced by the enclosed copy of the Recordation submitted to the U.S. Patent and Trademark Office on April 11, 2005, of the Confirmatory Assignment to Prosidion from Probiobdrug – which itself was the holder of 100% interest in an assignment from Probiobdrug Gesellschaft für Arzneimittelforschung MbH at Reel 012673, Frame 0628, and the inventors recorded at Reel 011326, Frame 0496 on November 28, 2000. As the assignee of 100% interest, Prosidion hereby revokes all previous powers of attorney given in the above-identified application and hereby appoints the patent practitioners in the Legal Department of OSI Pharmaceuticals, Inc. registered to practice before the U.S. Patent and Trademark Office.

They are presently Shu M. Lee, registration No. 41,147, Kimberly Nguyen, registration No. 47,821, and Alexander Stewart, registration No. 47,110.

Further, Assignee requests change of Correspondence Address to the address below, associated with **Customer Number 538724**. Commissioner is authorized to charge any deficiencies in fees and credit any overpayment to OSI Pharmaceuticals, Inc. Deposit Account No. **50-2783**.


Very truly yours,


Anker Lundemose
Chief Executive Officer
Prosidion Limited

8 June, 2005

Attorney for Applicants can be reached at the telephone number and address below.

Very truly yours,


Shu M. Lee
Attorney for Applicants
Registration No. 41,147
Telephone No. (631) 962-2056
or (516) 924-4035
Fax No. (631) 752-3880

08 June, 2005
OSI Pharmaceuticals, Inc.
58 South Service Road, Suite 110
Melville, NY 11747



Form PTO-1595 (Rev. 03/05)
OMB No. 0651-0027 (exp. 6/30/2005)

U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

RECORDATION FORM COVER SHEET PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies)

PROBIODRUG AG

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance/Execution Date(s):

Execution Date(s) 21 Mar 2005, 05 April 2005

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Joint Research Agreement
☐ Government Interest Assignment
☐ Executive Order 9424, Confirmatory License
☐ Other _____

2. Name and address of receiving party(ies)

Name: PROSIDION LIMITED

Internal Address: _____

Street Address: Windrush Court, Watlington Road

City: Oxford, OX4 6LT

State: _____

Country: United Kingdom

Zip: _____

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application or patent number(s):

☐ This document is being filed together with a new application.

A. Patent Application No.(s)

11/042,562,60/368197,10/117022,11/022087,09/932546,10/970526
10/200919,
10/361956,10/727209,09/745776,10/735582,09/745883
09/682968,10/246817,10/667200,60/443417,10/839122,
60/467914,60/499535,60/507408

B. Patent No.(s)

Additional numbers attached? ☒ Yes ☐ No

5. Name and address to whom correspondence concerning document should be mailed:

Name: Alison Blakey

Internal Address: _____

Street Address: Windrush Court, Watlington Road

City: Oxford, OX4 6LT, United Kingdom

State: _____ Zip: _____

Phone Number: 011 44 1865 782634

Fax Number: 011 44 1865 782601

Email Address: ablakey@prosidion.com

6. Total number of applications and patents involved: 44

7. Total fee (37 CFR 1.21(h) & 3.41) \$ 1,740.00

- ☐ Authorized to be charged by credit card
☐ Authorized to be charged to deposit account
☒ Enclosed
☐ None required (government interest not affecting title)

8. Payment Information

a. Credit Card Last 4 Numbers _____

Expiration Date _____

b. Deposit Account Number 50-2783

Authorized User Name Shu Muk Lee

9. Signature:

Shu Muk Lee

Signature

11 April 2005
Date

Shu Muk Lee Reg # 41,147
Name of Person Signing

Total number of pages including cover sheet, attachments, and documents: 4

CONFIRMATORY ASSIGNMENT

WHEREAS PROBIODRUG AG (formerly Probiodrug Gesellschaft für Arzneimittelforschung mbH) of Weinbergweg 22, 06120 Halle/Saale, Germany with its seat in Halle and registered with the commercial register of the local court of Halle-Saalkreis under folio no. HRB 13719, ("**Assignor**") is owner of the US Patent s and Patent Applications indicated in the schedule hereto ("**Patents**");

WHEREAS **Assignor** has by virtue of an Asset Transfer Agreement dated 17 June 2004 ("**Asset Transfer Agreement**") assigned the **Patents** to PROSIDION LIMITED (formerly OSI Diabetes Limited), a company registered in England and Wales under registered number 4600121 and having its registered office at Windrush Court, Watlington Road, Oxford, OX4 6LT, UK ("**Assignee**");

NOW, THEREFORE, to all whom it may concern be it known that **Assignor** having received good and valuable consideration from **Assignee** hereby confirms the assignment and transfer to **Assignee** with full title guarantee, free from all and any encumbrances, charges or other third party rights, of all right title and interest in the **Patents** including any continuation applications, divisional applications or continuation-in-part applications relating to such **Patents** and any patent applications or patents corresponding to or claiming priority from such **Patents** anywhere in the world and any extensions of the exclusivity granted in connection with such **Patents**, including but not limited to, extensions granted under the US Drug Price Competition and Patent Term Restoration Act 1984 and the EC Supplementary Protection Certificate Regulation (Council Regulation (EEC No 1768/92) and any legislation amending, replacing or implementing the foregoing; and including the right to recover and take all such proceedings as may be necessary for the recovery of damages or otherwise in respect of all infringements of any of the **Patents**, whether committed before or after the date of the **Asset Transfer Agreement**.

For PROBIODRUG AG:

Signed: _____

Name: Dr Hans-Ulrich Demuth

Capacity: Chief Executive Officer

Date: 21.03.2005

For PROSIDION LIMITED:

Signed: _____

Name: Dr Anker Lundemose

Capacity: Chief Executive Officer

Date: 5.04.05

SCHEDULE

PATENTS

10/186177
60/301158
6500804
10/216349
11/069544
10/196038
10/200870
60/194061
90/006954
10/676832
10/910176
10/287300
10/914261
60/340182
10/216305
60/340151
60/360909
10/244347
10/779158
10/397160
11/042562
60/368197
6303661
10/117022
11/022087
09/932546
10/970526
10/200919
6548481
10/361956
10/727209
09/745776
10/735582
09/745883
6319893
09/682968
6559314
10/246817
10/667200
60/443417
10/839122
60/467914
60/499535
60/507408